Although with controversial results, medications such as metformin, GLP-1, losartan, statin, growth hormone, and dipeptidyl peptidase 4 inhibitors can also have been considered and can alter the sarcopenic’s metabolic parameters, protect against cardiovascular diseases and outcomes while protecting muscles. The gene discussed is GLP1R; the disease is cardiovascular disorder.